Aethlon Medical Reports Hemopurifier Removes Inflammatory Extracellular Vesicles in Long COVID Study

Reuters12-02

Aethlon Medical Reports Hemopurifier Removes Inflammatory Extracellular Vesicles in Long COVID Study

Aethlon Medical Inc. has announced the publication of preclinical data demonstrating that the GNA affinity resin in its Hemopurifier® device binds to extracellular vesicles (EVs) in plasma samples from Long COVID patients and decreases inflammatory microRNAs. The results, published on November 20, 2025, in the pre-print archive bioRxiv, indicate that the Hemopurifier® removes both large and small EVs, which are elevated in Long COVID patients compared to recovered controls. Additionally, NanoString analyses identified seven EV-associated microRNAs significantly reduced by treatment with the GNA affinity resin. The company stated that these findings support further investigation of the Hemopurifier® in Long COVID. The results from this preclinical study have been submitted for consideration to a peer-reviewed journal and have not yet been presented in a clinical trial context.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA36107) on December 02, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588053472?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-02 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588053472","market":"nz","top_or_hot":-1,"title":"Aethlon Medical Reports Hemopurifier Removes Inflammatory Extracellular Vesicles in Long COVID Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aethlon Medical Reports Hemopurifier Removes Inflammatory Extracellular Vesicles in Long COVID Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AEMD\">Aethlon Medical Inc</a>. has announced the publication of preclinical data demonstrating that the GNA affinity resin in its Hemopurifier® device binds to extracellular vesicles (EVs) in plasma samples from Long COVID patients and decreases inflammatory microRNAs. The results, published on November 20, 2025, in the pre-print archive bioRxiv, indicate that the Hemopurifier® removes both large and small EVs, which are elevated in Long COVID patients compared to recovered controls. Additionally, NanoString analyses identified seven EV-associated microRNAs significantly reduced by treatment with the GNA affinity resin. The company stated that these findings support further investigation of the Hemopurifier® in Long COVID. The results from this preclinical study have been submitted for consideration to a peer-reviewed journal and have not yet been presented in a clinical trial context.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA36107) on December 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aethlon Medical Reports Hemopurifier Removes Inflammatory Extracellular Vesicles in Long COVID Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAethlon Medical Reports Hemopurifier Removes Inflammatory Extracellular Vesicles in Long COVID Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-02 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aethlon Medical Reports Hemopurifier Removes Inflammatory Extracellular Vesicles in Long COVID Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AEMD\">Aethlon Medical Inc</a>. has announced the publication of preclinical data demonstrating that the GNA affinity resin in its Hemopurifier® device binds to extracellular vesicles (EVs) in plasma samples from Long COVID patients and decreases inflammatory microRNAs. The results, published on November 20, 2025, in the pre-print archive bioRxiv, indicate that the Hemopurifier® removes both large and small EVs, which are elevated in Long COVID patients compared to recovered controls. Additionally, NanoString analyses identified seven EV-associated microRNAs significantly reduced by treatment with the GNA affinity resin. The company stated that these findings support further investigation of the Hemopurifier® in Long COVID. The results from this preclinical study have been submitted for consideration to a peer-reviewed journal and have not yet been presented in a clinical trial context.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA36107) on December 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美国抗疫概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL54kBQw:1","article_id":"2588053472","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588053472","pubTimestamp":1764680572,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aethlon Medical Inc. has announced the publication of preclinical data demonstrating that the GNA affinity resin in its Hemopurifier device binds to extracellular vesicles  in plasma samples from Long COVID patients and decreases inflammatory microRNAs. The results, published on November 20, 2025, in the pre-print archive bioRxiv, indicate that the Hemopurifier removes both large and small EVs, which are elevated in Long COVID patients compared to recovered controls. Additionally, NanoString analyses identified seven EV-associated microRNAs significantly reduced by treatment with the GNA affinity resin. The company stated that these findings support further investigation of the Hemopurifier in Long COVID. The results from this preclinical study have been submitted for consideration to a peer-reviewed journal and have not yet been presented in a clinical trial context.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT str","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","BK4583":"猴痘概念","AEMD":"Aethlon Medical Inc","BK4082":"医疗保健设备"},"translate_title":"Aethlon Medical报告血液净化器在新冠后遗症病研究中去除炎性细胞外囊泡","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AEMD":0.9},"content_text":"Aethlon Medical Reports Hemopurifier Removes Inflammatory Extracellular Vesicles in Long COVID Study\n    \n\nAethlon Medical Inc. has announced the publication of preclinical data demonstrating that the GNA affinity resin in its Hemopurifier® device binds to extracellular vesicles (EVs) in plasma samples from Long COVID patients and decreases inflammatory microRNAs. The results, published on November 20, 2025, in the pre-print archive bioRxiv, indicate that the Hemopurifier® removes both large and small EVs, which are elevated in Long COVID patients compared to recovered controls. Additionally, NanoString analyses identified seven EV-associated microRNAs significantly reduced by treatment with the GNA affinity resin. The company stated that these findings support further investigation of the Hemopurifier® in Long COVID. The results from this preclinical study have been submitted for consideration to a peer-reviewed journal and have not yet been presented in a clinical trial context.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA36107) on December 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588053472","isCrawlerRequest":true}